secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-032145
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech Q3 revenues surge 124% to $13M; net loss narrows to $1.5M
------------------------------------------------------------------------

- Q3 revenue $13.0M (up 124% YoY); nine-month revenue $30.5M (up 78%); includes $3.0M from Scendia acquisition.
- Gross margin 87% for nine months, down from 91% due to lower margins on Scendia products.
- SG&A $12.1M (+75%); R&D $1.1M (vs $0.04M a year ago) driven by Precision Healing and new development projects.
- Net loss improved to $1.5M from $2.0M on $1.7M non-cash tax benefit; nine-month net loss $3.9M vs $4.4M.
- Operational: record monthly revenue >$4M; post-quarter partnership with InfuSystem; FDA 510(k) submission for BIASURGE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315222032145/0001493152-22-032145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315222032145/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer